Literature DB >> 33446201

Structural alteration of lung parenchyma in patients with NF1: a phenotyping study using multidetector computed tomography (MDCT).

Maxim Avanesov1, Lennart Well2, Azien Laqmani2, Thorsten Derlin3, Vincent M Riccardi4, Gerhard Adam2, Victor-Felix Mautner5, Johannes Salamon2.   

Abstract

BACKGROUND: Diffuse interstitial lung disease have been described in Neurofibromatosis type 1 (NF1), but its diversity and prevalence remain unknown. The aim of this study was to assess the prevalence and characteristics of (NF1)-associated lung manifestations in a large single-center study using multidetector computed tomography (MDCT) and to evaluate the smoking history, patients' age, genetics, and the presence of malignant peripheral nerve sheath tumors (MPNST) as potential influencing factors for lung pathologies.
METHODS: In this retrospective study, 71 patients with NF1 were evaluated for the presence of distinctive lung manifestations like reticulations, consolidations, type of emphysema, pulmonary nodules and cysts. All patients underwent F-18-FDG PET/CT scans, which were reviewed by two experienced radiologists in consensus. Patients' subgroups were formed based on their smoking history (current smokers/previous smokers/never smokers), age (< 12 years, 12-18 years, > 18 years), and presence of MPNST (MPNST/no MPNST). In 57 patients (80%), genetic analysis of sequences coding for the neurofibromin on chromosome 17 was performed, which was correlated with different lung pathologies.
RESULTS: Among all NF1 patients (33 ± 14 years, 56% females), 17 patients (24%) were current smokers and 62 patients (87%) were > 18 years old. Pulmonary cysts, nodules, and paraseptal emphysema were the most common pulmonary findings (35%, 32%, 30%). The presence of pulmonary metastases, MPNST and centrilobular emphysema was associated with smoking. Cysts were observed only in adults, whereas no significant correlation between age and all other pulmonary findings was found (p > 0.05). Presence of MPNST was accompanied by higher rates of intrapulmonary nodules and pulmonary metastasis. Neither the presence nor absence of any of the specific gene mutations was associated with any particular lung pathology (p > 0.05).
CONCLUSIONS: All pulmonary findings in NF1 patients occurred independently from specific mutation subtypes, suggesting that many NF1 mutations can cause various pulmonary pathologies. The presence of pulmonary metastases, MPNST and centrilobular emphysema was associated with smoking, indicating the value of smoking secession or the advice not to start smoking in NF1 patients as preventive strategy for clinicians. For screening of pulmonary manifestations in NF1 patients, an MDCT besides medical history and physical examination is mandatory in clinical routine.

Entities:  

Keywords:  Emphysema; MDCT; Malignant peripheral nerve sheath tumor; Neurofibromatosis 1; Pulmonary cysts; Pulmonary nodules

Mesh:

Year:  2021        PMID: 33446201      PMCID: PMC7809820          DOI: 10.1186/s13023-021-01672-0

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.123


  33 in total

Review 1.  Genetic interstitial lung disease.

Authors:  Megan Stuebner Devine; Christine Kim Garcia
Journal:  Clin Chest Med       Date:  2011-12-06       Impact factor: 2.878

Review 2.  Neurofibromatosis-associated lung disease: a case series and literature review.

Authors:  A C Zamora; H R Collard; P J Wolters; W R Webb; T E King
Journal:  Eur Respir J       Date:  2006-07-26       Impact factor: 16.671

Review 3.  Upper lobe-predominant diseases of the lung.

Authors:  Stefan F Nemec; Alexander A Bankier; Ronald L Eisenberg
Journal:  AJR Am J Roentgenol       Date:  2013-03       Impact factor: 3.959

4.  Cigarette smoke activates the proto-oncogene c-src to promote airway inflammation and lung tissue destruction.

Authors:  Patrick Geraghty; Andrew Hardigan; Robert F Foronjy
Journal:  Am J Respir Cell Mol Biol       Date:  2014-03       Impact factor: 6.914

5.  NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.

Authors:  E Dombi; J Solomon; A J Gillespie; E Fox; F M Balis; N Patronas; B R Korf; D Babovic-Vuksanovic; R J Packer; J Belasco; S Goldman; R Jakacki; M Kieran; S M Steinberg; B C Widemann
Journal:  Neurology       Date:  2007-01-10       Impact factor: 9.910

6.  Internal tumor burden in neurofibromatosis Type I patients with large NF1 deletions.

Authors:  Lan Kluwe; Rosa Nguyen; Julia Vogt; Kathrin Bengesser; Tanja Mussotter; Reinhard E Friedrich; Kimberly Jett; Hildegard Kehrer-Sawatzki; Victor-Felix Mautner
Journal:  Genes Chromosomes Cancer       Date:  2012-02-01       Impact factor: 5.006

7.  Cigarette smoking and the risk of pulmonary metastasis from breast cancer.

Authors:  S Murin; J Inciardi
Journal:  Chest       Date:  2001-06       Impact factor: 9.410

Review 8.  Neurofibromatosis type 1.

Authors:  David H Gutmann; Rosalie E Ferner; Robert H Listernick; Bruce R Korf; Pamela L Wolters; Kimberly J Johnson
Journal:  Nat Rev Dis Primers       Date:  2017-02-23       Impact factor: 52.329

9.  Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain.

Authors:  R Fahsold; S Hoffmeyer; C Mischung; C Gille; C Ehlers; N Kücükceylan; M Abdel-Nour; A Gewies; H Peters; D Kaufmann; A Buske; S Tinschert; P Nürnberg
Journal:  Am J Hum Genet       Date:  2000-03       Impact factor: 11.025

10.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1987-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.